# Hemispherian AS

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hemispherian

- Industry: Biotechnology
- Headquarters: Oslo, Norway
- Website: www.hemispherian.com
- Total disclosed funding: $4.3M
- Latest round: Series A (Nov 24, 2022)
- Investors on record: 2

## About

Founded in 2015 and based in Oslo, Norway, Hemispherian AS operates as a biotechnology research firm that develops new cancer treatments. The company is developing small molecule drugs (GLIX) that target the TET2 enzyme and activate the DNA damage response, resulting in cancer cell death.

## Funding rounds

- Series A, Nov 24, 2022, $3M — Meneldor, Invest-NL
- Seed, May 3, 2022, $1.3M — Meneldor

## Investors

- Meneldor (https://capitalatlas.ai/funds/meneldor) — Seed, Series A
- Invest-NL — Series A